Target Name: MIR1301
NCBI ID: G100302246
Review Report on MIR1301 Target / Biomarker Content of Review Report on MIR1301 Target / Biomarker
MIR1301
Other Name(s): MicroRNA 1301 | hsa-miR-1301-3p | mir-1301 | microRNA 1301 | hsa-miR-1301-5p | MIRN1301 | hsa-mir-1301

MIR1301: A Potential Drug Target and Biomarker

MIR1301, a protein expressed in the human placenta, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique expression pattern and structural features make it an attractive target for small molecule inhibitors. In this article, we will discuss the biology of MIR1301, its potential drug targets, and its potential as a biomarker for disease.

MIR1301 is a transmembrane protein that is expressed in various tissues and organs, including the placenta, liver, and spleen. It is a member of the Tetraspan gene family, which includes proteins that are involved in the regulation of cell-cell interactions, cell signaling, and intracellular signaling pathways. MIR1301 is characterized by its unique expression pattern, which is primarily expressed in the placenta, and its unique structural features, including a N-terminal calbindin-like domain and a C-terminal secreted sphingomyelinase-like domain.

MIR1301 has been shown to play a role in various physiological processes, including cell signaling, angiogenesis, and placenta development. It has been shown to be involved in the regulation of cell proliferation, survival, and angiogenesis, which are critical processes for the development and maintenance of tissues and organs. MIR1301 has also been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway, which plays a critical role in cell signaling and growth regulation.

MIR1301 has been identified as a potential drug target due to its unique expression pattern and structural features. Small molecule inhibitors have been shown to be effective in blocking MIR1301's activity, leading to the potential for the development of new treatments for various diseases.

MIR1301 has been shown to be involved in the regulation of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. MIR1301 has been shown to be expressed in the brains of individuals with Alzheimer's disease and to play a role in the regulation of neurodegeneration. Similarly, MIR1301 has been shown to be involved in the regulation of neurotransmitter release in the brain, which is critical for the regulation of mood, anxiety, and other neurological disorders.

MIR1301 has also been shown to be involved in the regulation of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. MIR1301 has been shown to be expressed in the immune cells of individuals with rheumatoid arthritis and to play a role in the regulation of immune cell function. Similarly, MIR1301 has been shown to be involved in the regulation of T cell function, which is critical for the regulation of immune responses.

In conclusion, MIR1301 is a unique protein that has been shown to play a critical role in various physiological processes. Its unique expression pattern and structural features make it an attractive target for small molecule inhibitors. Further research is needed to fully understand the biology of MIR1301 and its potential as a drug target and biomarker for various diseases.

Protein Name: MicroRNA 1301

The "MIR1301 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1301 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305 | MIR1306 | MIR1307 | MIR130A | MIR130B | MIR132 | MIR1321 | MIR1322 | MIR1323 | MIR1324 | MIR133A1 | MIR133A1HG | MIR133A2 | MIR133B | MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911